Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.

ABSTRACT:

Background

Patients with rheumatoid arthritis (RA) are at increased risk for infection after arthroplasty, yet risks of specific biologic medications are unknown.

Objective

To compare risk for postoperative infection among biologics and to evaluate the risk associated with glucocorticoids.

Design

Retrospective cohort study.

Setting

Medicare and Truven MarketScan administrative data from January 2006 through September 2015.

Patients

Adults with RA who were having elective inpatient total knee or hip arthroplasty, either primary or revision, and had a recent infusion of or prescription for abatacept, adalimumab, etanercept, infliximab, rituximab, or tocilizumab before surgery.

Measurements

Propensity-adjusted analyses using inverse probability weigh

SUBMITTER: George MD 

PROVIDER: S-EPMC7197029 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature